Lupin Updates on VISUfarma Acquisition Timeline
Filing Summary
Lupin Ltd has provided an update on its acquisition of VISUfarma B.V., Netherlands. The transaction, initially expected to conclude by February 28, 2026, is now anticipated to complete in April 2026. The delay is due to pending satisfaction of specific closing conditions. Lupin’s wholly owned subsidiary, Nanomi B.V., is managing the acquisition. The company had previously communicated about this transaction in September and December 2025. This update is in compliance with Regulation 30 of the SEBI Listing Regulations.
Lupin Ltd has issued an update regarding its acquisition of VISUfarma B.V., a company based in the Netherlands. The acquisition is being conducted through Nanomi B.V., a wholly owned subsidiary of Lupin.
The definitive agreement to acquire the entire share capital of VISUfarma was initially communicated in September and December 2025. The transaction was originally expected to be completed by February 28, 2026. However, Lupin has now informed that the completion is anticipated in April 2026. This extension is due to the pending satisfaction of specific closing conditions.
This update is provided under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Lupin has communicated this information to the National Stock Exchange of India Limited and BSE Limited for dissemination.
Lupin Ltd is a global pharmaceutical company engaged in the development, production, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company focuses on delivering high-quality and affordable medicines to patients worldwide.